CLIA Waiver Authority Shifts To FDA; IVD Office Ready To Test New Methods
This article was originally published in The Gray Sheet
Executive Summary
CDRH is encouraging manufacturers to work with its in vitro diagnostics office to pilot new ways to meet CLIA waiver criteria
You may also be interested in...
FDA Draft Guidance Will Aim To Increase CLIA Waiver Flexibility
FDA plans to release a CLIA waiver draft guidance by year end, according to the Office of In Vitro Diagnostic Devices Evaluation & Safety
FDA Draft Guidance Will Aim To Increase CLIA Waiver Flexibility
FDA plans to release a CLIA waiver draft guidance by year end, according to the Office of In Vitro Diagnostic Devices Evaluation & Safety
CLIAC Waiver Criteria Input Readied As FDA Gears Up To Draft Guidance
The Clinical Laboratory Improvement Advisory Committee is close to issuing waiver recommendations, after agreeing to largely adopt criteria developed by its CLIA waiver workgroup